$-0.06
(Market cap
$1,500 Mln
Recently Viewed
Clear AllMarket cap
$1,500 Mln
Revenue (TTM)
$264 Mln
P/E Ratio
--
P/B Ratio
2.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.6 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-8.7
Debt to Equity
0.1
Book Value
$1.7
EPS
$-1
Face value
--
Shares outstanding
411,961,607
CFO
$-1,486.18 Mln
EBITDA
$-1,911.10 Mln
Net Profit
$-1,914.31 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Iovance Biotherapeutics (IOVA)
| 37.2 | -5.4 | 68.7 | 15.9 | -12.8 | -34.2 | -4.2 |
|
BSE Sensex
| -7.9 | 4.6 | -6.5 | 1.6 | 8.9 | 9.8 | 11.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Iovance Biotherapeutics (IOVA)
| -63.1 | -8.9 | 27.2 | -66.5 | -58.9 | 67.6 | 212.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Iovance Biotherapeutics (IOVA)
|
3.8 | 1,499.5 | 263.5 | -391.0 | -150.7 | -55.5 | -- | 2.1 |
| 67.6 | 9,338.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 41.7 | 15.7 | |
| 241.1 | 15,338.5 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 78.1 | |
| 64.2 | 8,171.9 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.2 | 12,295.6 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.5 | 5.4 | |
| 85.3 | 11,333.1 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 519.9 | 12,043.3 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.0 | |
| 526.1 | 14,850.2 | 2,530.2 | 451.1 | 21.3 | 70.2 | 34 | 32.3 | |
| 102.7 | 8,256.4 | 0.0 | -425.4 | -- | -36.7 | -- | 6.6 | |
| 316.9 | 9,569.6 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the... United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. Address: 825 Industrial Road, San Carlos, CA, United States, 94070 Read more
Interim CEO, President, General Counsel & Corporate Secretary
Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Interim CEO, President, General Counsel & Corporate Secretary
Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Headquarters
San Carlos, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Iovance Biotherapeutics Inc (IOVA) is $3.76 (NASDAQ) as of 16-Apr-2026 12:38 EDT. Iovance Biotherapeutics Inc (IOVA) has given a return of -12.76% in the last 3 years.
Since, TTM earnings of Iovance Biotherapeutics Inc (IOVA) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2.84
|
1.59
|
|
2024
|
-6.06
|
3.18
|
|
2023
|
-4.69
|
3.56
|
|
2022
|
-2.70
|
2.11
|
|
2021
|
-9.14
|
4.82
|
The 52-week high and low of Iovance Biotherapeutics Inc (IOVA) are Rs 5.63 and Rs 1.64 as of 17-Apr-2026.
Iovance Biotherapeutics Inc (IOVA) has a market capitalisation of $ 1,500 Mln as on 15-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Iovance Biotherapeutics Inc (IOVA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.